Kalaris Therapeutics, Inc. Operating Income Loss

• Kalaris Therapeutics, Inc. showed an increase of +10.8% in Operating Income Loss from 2024 to 2025.
• This data is from Kalaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Kalaris Therapeutics, Inc.'s Operating Income Loss has declined by 72.8%.
• Historical annual values: Fiscal year 2025: -$46.15 million | Fiscal year 2024: -$51.73 million | Fiscal year 2023: -$199.90 million | Fiscal year 2022: -$171.20 million | Fiscal year 2021: -$169.82 million | Fiscal year 2020: -$71.31 million | Fiscal year 2019: -$26.70 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026